Effectiveness of zinc supplementation as an adjunct therapy in managing idiopathic pulmonary fibrosis
Not Applicable
Not yet recruiting
- Conditions
- Idiopathic Pulmonary FibrosisRespiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12624001171505
- Lead Sponsor
- University of Adelaide
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Patients 40 years of age or older who have received a diagnosis of IPF according to 2022 international guidelines and confirmed by a multidisciplinary team.
Exclusion Criteria
IPF patients with severe co-existing medical conditions as determined by the investigators such as but not limited to advanced cardiovascular diseases, uncontrolled diabetes, or malignancies.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Lung function[Spirometry assessment of Forced vital capacity (FVC; measured as a percentage of predicted value) among IPF patients FVC will be measured at baseline, 6 months, and 12 months (primary timepoint) post-baseline]
- Secondary Outcome Measures
Name Time Method Pulmonary hypertension[Echocardiographic assessment of pulmonary arterial pressure Baseline and every 6 months over 12 months post-baseline];Number of acute exacerbations [Physician review and chest X-ray assess for the presence of parenchymal abnormalities in lung tissue without signs of collapsed lungs (pneumothorax) or fluid around the lungs (pleural effusion) since the last visit Baseline and every 3 months over 12 months post-baseline];Number of acute exacerbations days[ Physician evaluation and chest X-ray to assess for parenchymal abnormalities in lung tissue, while ensuring there are no signs of lung collapse (pneumothorax) or fluid accumulation around the lungs (pleural effusion) since the last visit. Baseline and every 3 months over 12 months post-baseline]